These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 27012367)

  • 1. Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer.
    Paul S; Lal G
    Int J Cancer; 2016 Sep; 139(5):976-85. PubMed ID: 27012367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
    Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
    Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
    Gomes AQ; Martins DS; Silva-Santos B
    Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of gamma/delta T cells for solid tumor immunotherapy.
    Zhu D; Ren X; Xie W; Chen J; Liang S; Jiang M; Wang J; Zheng Z
    Front Immunol; 2024; 15():1466266. PubMed ID: 39253082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
    Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
    J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Porcine T lymphocytes and NK cells--an update.
    Gerner W; Käser T; Saalmüller A
    Dev Comp Immunol; 2009 Mar; 33(3):310-20. PubMed ID: 18601948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells.
    Haas JD; González FH; Schmitz S; Chennupati V; Föhse L; Kremmer E; Förster R; Prinz I
    Eur J Immunol; 2009 Dec; 39(12):3488-97. PubMed ID: 19830744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
    Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
    Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
    Li Y; Li G; Zhang J; Wu X; Chen X
    Front Immunol; 2020; 11():619954. PubMed ID: 33664732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
    Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
    Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases.
    Lopez RD
    Immunol Res; 2002; 26(1-3):207-21. PubMed ID: 12403359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of human gammadelta T lymphocytes for immunotherapy of cancer.
    Kabelitz D; Wesch D; Pitters E; Zöller M
    Int J Cancer; 2004 Dec; 112(5):727-32. PubMed ID: 15386388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct metabolic programs established in the thymus control effector functions of γδ T cell subsets in tumor microenvironments.
    Lopes N; McIntyre C; Martin S; Raverdeau M; Sumaria N; Kohlgruber AC; Fiala GJ; Agudelo LZ; Dyck L; Kane H; Douglas A; Cunningham S; Prendeville H; Loftus R; Carmody C; Pierre P; Kellis M; Brenner M; Argüello RJ; Silva-Santos B; Pennington DJ; Lynch L
    Nat Immunol; 2021 Feb; 22(2):179-192. PubMed ID: 33462452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells.
    Urban EM; Chapoval AI; Pauza CD
    Clin Dev Immunol; 2010; 2010():732893. PubMed ID: 20396597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. gammadelta-T cells expressing NK receptors predominate over NK cells and conventional T cells in the innate IFN-gamma response to Plasmodium falciparum malaria.
    D'Ombrain MC; Hansen DS; Simpson KM; Schofield L
    Eur J Immunol; 2007 Jul; 37(7):1864-73. PubMed ID: 17557374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. γδ T cell-based anticancer immunotherapy: progress and possibilities.
    Meraviglia S; Lo Presti E; Dieli F; Stassi G
    Immunotherapy; 2015; 7(9):949-51. PubMed ID: 26569071
    [No Abstract]   [Full Text] [Related]  

  • 19. Pro-tumor γδ T Cells in Human Cancer: Polarization, Mechanisms of Action, and Implications for Therapy.
    Chabab G; Barjon C; Bonnefoy N; Lafont V
    Front Immunol; 2020; 11():2186. PubMed ID: 33042132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.
    Bartish M; Del Rincón SV; Rudd CE; Saragovi HU
    Front Immunol; 2020; 11():564499. PubMed ID: 33133075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.